Neuroleptic malignant syndrome associated with haloperidol treatment in a patient with head injury

Yen, Han-Lin; Tsai, Shih‐Chuan

doi:10.1016/j.fjs.2013.03.003

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dirençli olgular için elektrokonvulzif tedavi (EKT) uygulaması da tedavi önerileri arasında yer almaktadır(2)(3)(4)7). İyileşme takibinde CPK düzeyi ölçümleri kullanılabilir(10). Sunulan olgumuz yoğun bakım koşullarında takip edilmiş, bromokriptin (5 mg günde üç kez oral) ve uygun destek tedavi ile başlangıçta normal sınırların üzerinde olan CPK düzeyleri normal sınırlara dönmüş ve hasta klinik olarak iyileşme göstermiştir.…”

unclassified

“…İyileşme takibinde CPK düzeyi ölçümleri kullanılabilir(10). Sunulan olgumuz yoğun bakım koşullarında takip edilmiş, bromokriptin (5 mg günde üç kez oral) ve uygun destek tedavi ile başlangıçta normal sınırların üzerinde olan CPK düzeyleri normal sınırlara dönmüş ve hasta klinik olarak iyileşme göstermiştir.SonuçNMS yaşamı tehdit edebilen bir durum olduğundan klinisyenler tarafından mutlaka tanınması gereken bir tablodur.…”

unclassified

See 1 more Smart Citation

Neuroleptic Malignant Syndrome Associated with Quetiapine Treatment in a Patient with Ventriculoperitoneal Shunt

Zengin¹,

İçer²,

Gündüz³

et al. 2014

JAEMCR

View full text Add to dashboard Cite

Introduction: Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening idiosyncratic reaction during the use of antipsychotic drugs, usually beginning in the first 2 weeks of the treatment. NMS is generally manifested by muscle rigidity, hyperthermia, autonomic instability, altered mental status, tremors, elevated serum creatinine phosphokinase, and leukocytosis.Case Report: A 26-year-old male patient who had a ventriculoperitoneal (V-P) shunt was admitted to the emergency department with complaints of loss of consciousness, fever, respiratory distress, and palpitations. In his history, we learned that treatment of quetiapine 25 mg/day was initiated 6 months ago. After physical examination and laboratory results, the patient, who had a V-P shunt, was primarily considered shunt dysfunction or infection. But, with laboratory parameters and radiographic examinations, we moved away from this diagnosis. He was evaluated as NMS due to the history of antipsychotic drug using, fever, rigidity, tachycardia, tachypnea, confusion, and increase of creatine phosphokinase for the preliminary diagnosis. Since there was no any etiological factor that could explain the clinical process, he was admitted to the medical intensive care with a diagnosis of NMS.Conclusion: NMS is a disorder that can be life-threatening and must be recognized by clinicians.

show abstract

unclassified